

VEDOLIZUMAB (cont.)

and consider holding if one occurs. Do not coadminister with natalizumab, another integrin

antagonist that can cause progressive multifocal leukoencephalopathy. Do not coadminister with TNF-blockers.

GASTROENTEROLOGY: Other GI Agents**ALOSETRON (Lotronex) ▶ L ♀ B D? \$\$\$\$\$**

WARNING — Can cause severe constipation and ischemic colitis. Concomitant use with fluvoxamine, a potent CYP1A2 inhibitor, is contraindicated. Use caution with moderate CYP1A2 inhibitors such as quinolone antibiotics and cimetidine. Use caution with strong inhibitors of CYP3A4 such as ketoconazole, clarithromycin, protease inhibitors, voriconazole, and itraconazole.

ADULT — **Diarrhea-predominant irritable bowel syndrome in women who have failed conventional therapy:** 0.5 mg PO twice a day for 4 weeks; discontinue in patients who become constipated. If well tolerated and symptoms not controlled after 4 weeks, may increase to 1 mg PO two times per day. Discontinue if symptoms not controlled in 4 weeks on 1 mg PO two times per day.

PEDS — Not approved in children.

FORMS — Generic/Trade: Tabs 0.5, 1 mg.

NOTES — Prescribers should complete REMs program prior to prescribing.

ALPHA-GALACTOSIDASE (Beano) ▶ minimal absorption ♀? D? \$

ADULT — 1 tab per ½ cup gassy food, 2 to 3 tabs PO (chew, swallow, or crumble) or 1 melt-away tab per typical meal.

PEDS — Not approved in age younger than 12 yo.

FORMS — OTC Trade only: Tabs, melt-away tabs.

NOTES — Beano produces 2 to 6 g of carbohydrates for every 100 g of food treated by Beano; may increase glucose levels.

ALVIMOPAN (Entereg) ▶ intestinal flora ♀ B D? \$\$\$\$\$

WARNING — Increased risk of myocardial infarction in a clinical trial of patients taking alvimopan long-term. Only available through a restricted program for short-term use (15 doses).

ADULT — **To accelerate time to upper and lower gastrointestinal recovery following partial bowel resection with primary anastomosis, short-term (up to 15 doses) only:** 12 mg PO 30 min to 5 h prior to surgery, then 12 mg PO two times per day starting the day after surgery for up to 7 days.

PEDS — Not approved in children.

FORMS — Trade only: Caps 12 mg.

NOTES — Only available to hospitals that are authorized to use the medication (requires hospital DEA number to be dispensed). Contraindicated in patients who have taken therapeutic doses of opioids for more than 7 consecutive days. Not for use in those with severe hepatic or renal disease, or for gastric primary pancreatic anastomosis. Serum concentrations in patients of Japanese

descent may be up to 2-fold greater than Caucasian subjects with same dose. Monitor Japanese patients for adverse events.

BUDESONIDE (Entocort EC, Uceris) ▶ L ♀ C D? \$\$\$\$\$

ADULT — **Mild to moderate Crohn's, induction of remission:** 9 mg PO daily for up to 8 weeks. May repeat 8-week course for recurring episodes. 1 metered dose applied to rectal area twice daily for 2 weeks followed by 1 metered dose once daily for 4 weeks (Uceris foam). **Maintenance:** 6 mg PO daily for 3 months (Entocort only). **Mild to moderate ulcerative colitis, induction of remission:** 9 mg PO q am for up to 8 weeks.

PEDS — **Mild to moderate Crohn's disease in children 8 to 17 years:** 9 mg PO q am for up to 8 weeks, then 6 mg PO q am for 2 weeks.

UNAPPROVED PEDS — **Mild to moderate Crohn's in children younger than 8 years:** 0.45 mg/kg up to 9 mg PO daily for 8 to 12 weeks for age 9 yo or older.

FORMS — Generic/Trade: Caps 3 mg. Trade only: Extended-release tabs (Uceris) 9 mg. (Uceris for ulcerative colitis, only). Rectal foam (Uceris) 2 mg/metered dose, 14 actuations/canister.

NOTES — May taper dose to 6 mg for 2 weeks prior to discontinuation (Entocort).

CHENODIOL (Chenodal) ▶ bile L ♀ X D? varies by therapy

ADULT — **Gallstone dissolution:** 13 to 16 mg/kg/day in two divided doses, morning and night, starting with 250 mg two times per day the first 2 weeks and increasing by 250 mg/day each week thereafter until the recommended or max tolerated dose is reached.

PEDS — Not approved for use in children.

FORMS — Generic: Tabs 250 mg.

NOTES — Monitor LFTs.

CHLORDIAZEPOXIDE—CLIDINIUM ▶ K ♀ D—\$\$\$\$\$

ADULT — **Irritable bowel syndrome:** 1 to 2 caps PO three to four times per day.

PEDS — Not approved in children.

FORMS — Generic: Caps, chlordiazepoxide 5 mg + clidinium 2.5 mg.

NOTES — May cause drowsiness. After prolonged use, gradually taper to avoid withdrawal symptoms. Contains ingredients formerly contained in Librax.

CHOLIC ACID (Cholbam) ▶ bile L ♀? D? \$\$\$\$\$

ADULT — **Bile synthesis disorders:** 10 to 15 mg/kg PO once daily or in two divided doses. **Familial triglyceridemia:** 11 to 17 mg/kg PO once daily or in two divided doses.

PEDS — Use adult dosing.

FORMS — Trade: Capsules 50, 250 mg.

(cont.)